Licensing status

Publication and contact information


Colon cancer

BMI1 polycomb ring finger oncogene (BMI1)

In vitro and mouse studies suggest inhibiting BMI1 expression could help treat colon cancer. In cultured cancer-initiating cells from human colon tumors, shRNA knockdown of BMI1 prevented both cell self-renewal and the formation of tumors when cells were implanted into mice. In mouse xenograft models with established human colon cancer, PTC-209, a small molecule inhibitor of BMI1 expression, decreased cancer-initiating tumor cells and irreversibly decreased tumor volume compared with vehicle. Next steps include optimizing the BMI1 inhibitor series.
PTC Therapeutics Inc. has BMI1-expression inhibitors including PTC-596 and PTC-209 in preclinical testing for cancer.

SciBX 7(3); doi:10.1038/scibx.2014.83
Published online Jan. 23, 2014

Patent application filed by PTC Therapeutics; available for licensing

Kreso, A. et al. Nat. Med.;
published online Dec. 1, 2013;
Contact: John E. Dick, University Health Network, Toronto, Ontario, Canada